Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the Phase III LIGHTHOUSE trial (NCT04649060) designed to evaluate the efficacy and safety of melflufen plus dexamethasone and daratumumab compared to daratumumab alone in patients with relapsed/refractory (R/R) multiple myeloma, commenting on the partial clinical hold recently placed on the trial by the FDA. This trial is being conducted in a patient population who were previously treated with an immunomodulatory imide drug and a proteasome inhibitor. The primary objective is to show superiority of triple therapy, and key secondary objectives include overall response rate (ORR), duration of response and safety. Dr Richardson also sheds light on data from the Phase III OCEAN study (NCT03151811) comparing melflufen-dexamethasone with pomalidomide-dexamethasone after lenalidomide failure and the Phase I/II ANCHOR study (NCT03481556) comparing melflufen-dexamethasone plus bortezomib with daratumumab only. Both studies have shown promising results with the use of melflufen-dexamethasone in the R/R setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.